Roche Exit Wave’s Allele-Selective ASO in Huntington’s Disease
Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave Life Sciences and its allele-selective antisense oligonucleotide candidate, WVE-003.The key distinction is biological selectivity. Tominersen was designed to lower total…
